Tengion is a clinical stage regenerative medicine company that focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using its Autologous Organ Regeneration Platform™. Tengion’s technologies aim to cure — rather than treat — organ and tissue failure. Tengion uses biocompatible materials and a patient’s own (autologous) cells to create a functional neo-organ or neo-tissue that is designed to catalyze the body’s innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, including shortage of donor organs, the risk of organ rejection, and the high cost and toxicity of immunosuppressant medications, enabling people to lead healthier lives without donor transplants or the side effects of related therapies.
Website:
www.tengion.com
Safeguard Partner Company Since 2008